shoshin

No, but you said that the FDA caught the problem. Link?

The difference is that those outlets were wrong and didn't know it. Trump said he knew it was serious and 5x more deadly than the flu--and downplayed it, or you could say, lied about it. Big difference being the media wasn't downplaying it in that headline collage--they just got it wrong and changed their tune quickly as we all know. Also a difference: Trump is the President. Florida is 197 deaths (on a 3-day weekend catchup day) and only 2000 cases today. This could be the week where we see a big drop in fatalities, which I was expecting sooner. Tomorrow's post catchup #s will be interesting.

Your conspiracy stuff aside, this happened in the UK so the FDA is irrelevant.

Can't hate Tyrod. He was just not good enough and clearly not a long term answer. I don't know yet if Josh is either but I'm optimistic based on what I've seen that he can be. TT's 3 yard dump offs on 3rd and 9 drew out more curses than anything Josh has yet to do.

There are 150 politics threads at ganggreen....compared to 40,000+ football ones. You could bring it up if we were debating the closure of the Rochester Bills Fan Topics and have a good point. You all are looking for people to ignore. Look at this friggin' guy.

Interesting. I've not said PPP is full of wrong think. It is, however, full of what I believe to be bad behavior and it has a worse history. I made my example his threads because Rhino specifically asked the question.

Is your Twitter broken? Your internet cracked. Banned from google? Pretty sure your ability to share ideas is intact. I just favor making TBD a nicer place. End of story.

The incredible thing to me is not that Trump said or knew these things (or others knew and were telling him). It's that Trump would talk to Bob Woodward. Say what you will about Trump, he's 10000x more open than Obama ever was when it comes to media access. Is there anyone in the media today who could get as much access to the Obama AND Trump administrations as Woodward. It's impressive. And yeah, it looks pretty bad for Trump. No getting around that. I can't get to that paywall article but here's another version.

I think we will have a few identified by late 2020. Really hope AZ can get over this hurdle

AZ vaccine study temporarily halted. Hopefully they can get to the bottom of this and get it back on track--this is one of the vaccines expected to deliver in huge quantities quickly. https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/ https://www.nytimes.com/2020/09/08/health/coronavirus-astrazeneca-vaccine-safety.html A person familiar with the situation, who spoke on the condition of anonymity, said that the participant who experienced the suspected adverse reaction had been enrolled in a Phase 2/3 trial based in the United Kingdom. The individual also said that a volunteer in the U.K. trial had received a diagnosis of transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. However, the timing of this diagnosis, and whether it was directly linked to AstraZeneca’s vaccine, is still unknown. Transverse myelitis can result from a number of causes that set off the body’s inflammatory responses, including viral infections, said Dr. Gabriella Garcia, a neurologist at Yale New Haven Hospital. But, she added, the condition is often treatable with steroids.

It won't and being open is not all about the economy.

I welcome a season where we are complaining about the punter being the weak link. I remember too many seasons where Brian Moorman was the highlight.

That's well-reasoned. I believe the house rules are also OK with choosing which threads to participate in. B-Gal invited to me to participate in others. I decline.

No thank you. I see enough of how people act here.

From StatNews, just a good single location for all the vaccine progress to supplement Hapless's post above and IMO a little easier to digest quickly. The below is through 9/9. Coronavirus Vaccines Tracker : Sheet1 Company Stage Description Notes & Updates Related Coverage University of Oxford and AstraZeneca Phase 3 University of Oxford researchers have developed a potential vaccine that uses a harmless virus engineered to contain the genetic sequence that encodes for a protein on the surface of the novel coronavirus. The researchers, from the University’s Jenner Institute and Oxford Vaccine Group, are working at uncommon speed, starting a placebo-controlled clinical trial while finalizing the manufacturing of their potential vaccine. British drug maker AstraZeneca has partnered on the project. March 27: Oxford begins recruiting patients for a placebo-controlled trial that will enroll up to 510 healthy volunteers. The vaccine will not be ready for "some weeks," according to the university. April 30: AstraZeneca announces it will partner with Oxford to develop the vaccine. July 20: Oxford publishes Phase 1/2 data demonstrating an immune response with mild to moderate side effects. Aug. 31: AstraZeneca begins enrollment in a U.S. Phase 3 trial that will involved 30,000 volunteers. Sept. 8: AstraZeneca says a hold has been put on the trial following a suspected adverse reaction in a participant. Read more Moderna Therapeutics Phase 3 Moderna’s vaccine, mRNA-1273, is a synthetic messenger RNA that encodes for a protein found on the surface of the novel coronavirus. By compelling cells to produce that protein, the vaccine would spur an immune response, causing the body to generate antibodies that would protect against infection. The company set a drug industry record with mRNA-1273, identifying a vaccine candidate just 42 days after the novel coronavirus was sequenced. March 16: First patient dosed in a Phase 1 trial April 16: Moderna plans to begin a Phase 2 study by July May 1: Moderna announces it will partner with Swiss firm Lonza on development May 7: FDA clears Moderna to start a 600-patient Phase 2 study, which will begin "shortly" May 18: Moderna discloses interim Phase 1 data, in which eight volunteers developed antibodies to the coronavirus May 29: Moderna doses the first volunteers in a Phase 2 study, planning to enroll about 600 people July 14: Moderna publishes Phase 1 data showing a consistent antibody response and mild to moderate side effects. July 27: Moderna begins enrollment in a 30,000-subject Phase 3 trial Read More BioNTech and Pfizer Phase 3 Germany’s BioNTech is working on a multitude of mRNA vaccines for the novel coronavirus, planning to develop them in parallel. Like its competitors, the company uses strands of mRNA to generate protective antibodies. Earlier this month, Shanghai’s Fosun Pharma signed a deal to market BioNTech’s vaccine in China if it’s eventually approved. Pfizer has agreed to co-develop the vaccine in the rest of the world. April 9: BioNTech says it will begin its first human trials "as early as the end of April" April 29: BioNTech and Pfizer dose the first patients in a Phase 1 trial in Germany, planning to enroll about 200 patients May 5: BioNTech and Pfizer begin Phase 1 study in the U.S., recruiting up to 360 patients total May 12: BioNTech says it expects preliminary data in June or July July 1: In a Phase 1 trial, BioNTech's vaccine led to an increase coronavirus antibodies at three doses, according to a preprint paper July 27: Pfizer and BioNTech begin enrollment on a 30,000-volunteer study, expecting data as early as October Read more Sinovac Phase 2 Sinovac, headquartered in Beijing, is developing a vaccine using an inactivated version of the novel coronavirus. The company used the same technology to craft approved vaccines for hepatitis A and B; swine flu; avian flu; and the virus that causes hand, foot, and mouth disease. April 17: Sinovac begins a placebo-controlled Phase 1/2 trial, planning to enroll 144 healthy volunteers in China May 6: Sinovac publishes results from a preclinical study in which its vaccine successfully protected monkeys from contracting the novel coronavirus. The company plans to start a second, larger human trial by mid-May June 14: Sinovac released preliminary results from its Phase 2 trial, saying its vaccine induced neutralizing antibodies in “above 90%” of participants Read more CanSino Biologics Phase 2 CanSino Biologics, headquartered in Tianjin, is developing a coronavirus vaccine using the technology that led to a China-approved Ebola virus vaccine. CanSino’s approach involves taking a snippet of coronavirus’ genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. March 17: CanSino begins Phase 1 trial in China April 10: Based on preliminary data, CanSino says it will move into Phase 2 "soon" May 22: CanSino published data from a 108-subject trial, in which its vaccine generated a immune response in volunteers June 29: Chinese regulators provisionally approved CanSino's vaccine for military use July 20: CanSino publishes interim Phase 2 data showing a consistent antibody response but one that seemed to wane in older subjects Read more Inovio Pharmaceuticals Phase 1 Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, to produce the vaccine. April 6: Inovio doses first patient in Phase 1 trial June 30: Inovio says its vaccine led to an immune response in 94% of patients but does not provide data Read more Novavax Phase 1 Novavax is at work on a coronavirus vaccine that begins in the ovaries of an insect. The company’s vaccine platform involves genetically engineering a harmless virus and exposing it to cells isolated from worms. Those cells then churn out the proteins needed to stimulate antibodies, and those proteins become vaccines. For Covid-19, Novavax has isolated the spike protein found on the surface of the novel coronavirus. April 8: Novavax selects a vaccine candidate, planning to begin human trials in May with preliminary data in July May 26: Novavax begins Phase 1 trial, planning to enroll about 130 volunteers with data expected in July Aug. 4: Novavax presents detailed data from its Phase 1 trial, demonstrating an immune response with mostly mild side effects Read more Sanofi and GlaxoSmithKline Phase 1 Sanofi is employing the same technology it employs for flu vaccines, which uses a genetically modified version of a virus to create proteins that train the immune system to react. The company is combining its approach with GlaxoSmithKline's proprietary adjuvant, an additive that makes vaccines more potent. Feb. 18: Sanofi begins work on a coronavirus vaccine April 14: Sanofi partners with GlaxoSmithKline and plans to begin human trials in the second half of 2020 and generate pivotal data in 2021 Sept. 3. Sanofi and GlaxoSmithKline begin a 400-volunteer, Phase 1/2 trial, expect data in December Read More Johnson & Johnson Preclinical Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is using the same technology to develop a vaccine for the novel coronavirus. J&J’s vaccine is made by grafting the coronavirus genes that confer immunity onto a harmless virus, injecting it triggering an immune response without causing infection. March 30: J&J expects to begin Phase 1 by September, with a vaccine available for emergency use as soon as early 2021 Arcturus Therapeutics Preclinical Arcturus Therapeutics is pressing forward with a vaccine that relies on engineering RNA. The company plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle. The resulting vaccine, being developed in partnership with Duke University, promises a better immune response at a lower dose than competing mRNA approaches, according to the company. April 9: Arcturus plans to begin a Phase 1 trial in Singapore over the summer Clover Biopharmaceuticals and GlaxoSmithKline Preclinical Clover Biopharmaceuticals, headquartered in Chengdu, is developing a vaccine that would inject patients with a protein found on the surface of the novel coronavirus. GlaxoSmithKline is providing its proprietary adjuvant, an additive that makes vaccines more potent. Feb. 10: Clover identifies its vaccine candidate Feb. 24: GlaxoSmithKline provides its adjuvant CureVac Preclinical CureVac uses man-made mRNA to spur the production of proteins and protective antibodies. Like Moderna, the company got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. March 17: CureVac said it expects to have a candidate ready for animal testing by April, aiming to start a clinical study in the summer Imperial College London Preclinical Led by the immunologist Robin Shattock, Imperial College London is developing an RNA-based vaccine for the novel coronavirus. The scientists have engineered a virus-derived RNA strand that will get into cells, spur the production of the coronavirus’s signature protein, and then replicate itself. In animal studies, the vaccine has resulted in the generation of protective antibodies. April 17: With funding from the U.K. government, Imperial plans to complete preclinical work and begin human trials in June University of Queensland and GlaxoSmithKline Preclinical Australia’s University of Queensland, with funding from the Coalition for Epidemic Preparedness Innovations, has been developing a coronavirus vaccine since January. Queensland has a proprietary technology meant to make protein vaccines more effective at triggering an immune response. Called a molecular clamp, the university’s approach keeps the coronavirus’s key protein in its natural shape before grafting it onto the vaccine. April 9: Queensland plans to begin human trials in the third quarter Merck Preclinical Merck purchased a Vienna-based company called Themis, which is developing an experimental Covid-19 vaccine based on a measles vaccine. It also partnering with the nonprofit IAVI on the development of a coronavirus vaccine related to the company's existing Ebola vaccine. May 26: Merck says the Themis vaccine will enter human trials in a matter of weeks while the second candidate could reach the clinic by the end of the year Read more Sanofi and Translate Bio Preclinical Sanofi partnered with Translate Bio to develop potential vaccines using synthetic messenger RNA, which would compel the body to produce antibodies against the novel coronavirus. The two companies have worked together in the past on vaccines for infectuous disease. March 27: Sanofi and Translate Bio announce their collaboration but do not specify a development timeline

At some point, there will be a few vaccines available, and there already are some treatments. Probably the best vaccine tracker is the one at StatNews, which also has a treatment tracker. I will try to keep this updated every couple weeks and I pulled this out of the monster thread since that's dedicated to numbers tracking at this point, and this thread can maybe discuss the vaccines themselves. (There's another vaccine tracker at the NYTimes but it's not as user-friendly.) Coronavirus Vaccines Tracker : Sheet1 Company Stage Description Notes & Updates Related Coverage University of Oxford and AstraZeneca Phase 3 University of Oxford researchers have developed a potential vaccine that uses a harmless virus engineered to contain the genetic sequence that encodes for a protein on the surface of the novel coronavirus. The researchers, from the University’s Jenner Institute and Oxford Vaccine Group, are working at uncommon speed, starting a placebo-controlled clinical trial while finalizing the manufacturing of their potential vaccine. British drug maker AstraZeneca has partnered on the project. March 27: Oxford begins recruiting patients for a placebo-controlled trial that will enroll up to 510 healthy volunteers. The vaccine will not be ready for "some weeks," according to the university. April 30: AstraZeneca announces it will partner with Oxford to develop the vaccine. July 20: Oxford publishes Phase 1/2 data demonstrating an immune response with mild to moderate side effects. Aug. 31: AstraZeneca begins enrollment in a U.S. Phase 3 trial that will involved 30,000 volunteers. Sept. 8: AstraZeneca says a hold has been put on the trial following a suspected adverse reaction in a participant. Read more Moderna Therapeutics Phase 3 Moderna’s vaccine, mRNA-1273, is a synthetic messenger RNA that encodes for a protein found on the surface of the novel coronavirus. By compelling cells to produce that protein, the vaccine would spur an immune response, causing the body to generate antibodies that would protect against infection. The company set a drug industry record with mRNA-1273, identifying a vaccine candidate just 42 days after the novel coronavirus was sequenced. March 16: First patient dosed in a Phase 1 trial April 16: Moderna plans to begin a Phase 2 study by July May 1: Moderna announces it will partner with Swiss firm Lonza on development May 7: FDA clears Moderna to start a 600-patient Phase 2 study, which will begin "shortly" May 18: Moderna discloses interim Phase 1 data, in which eight volunteers developed antibodies to the coronavirus May 29: Moderna doses the first volunteers in a Phase 2 study, planning to enroll about 600 people July 14: Moderna publishes Phase 1 data showing a consistent antibody response and mild to moderate side effects. July 27: Moderna begins enrollment in a 30,000-subject Phase 3 trial Read More BioNTech and Pfizer Phase 3 Germany’s BioNTech is working on a multitude of mRNA vaccines for the novel coronavirus, planning to develop them in parallel. Like its competitors, the company uses strands of mRNA to generate protective antibodies. Earlier this month, Shanghai’s Fosun Pharma signed a deal to market BioNTech’s vaccine in China if it’s eventually approved. Pfizer has agreed to co-develop the vaccine in the rest of the world. April 9: BioNTech says it will begin its first human trials "as early as the end of April" April 29: BioNTech and Pfizer dose the first patients in a Phase 1 trial in Germany, planning to enroll about 200 patients May 5: BioNTech and Pfizer begin Phase 1 study in the U.S., recruiting up to 360 patients total May 12: BioNTech says it expects preliminary data in June or July July 1: In a Phase 1 trial, BioNTech's vaccine led to an increase coronavirus antibodies at three doses, according to a preprint paper July 27: Pfizer and BioNTech begin enrollment on a 30,000-volunteer study, expecting data as early as October Read more Sinovac Phase 2 Sinovac, headquartered in Beijing, is developing a vaccine using an inactivated version of the novel coronavirus. The company used the same technology to craft approved vaccines for hepatitis A and B; swine flu; avian flu; and the virus that causes hand, foot, and mouth disease. April 17: Sinovac begins a placebo-controlled Phase 1/2 trial, planning to enroll 144 healthy volunteers in China May 6: Sinovac publishes results from a preclinical study in which its vaccine successfully protected monkeys from contracting the novel coronavirus. The company plans to start a second, larger human trial by mid-May June 14: Sinovac released preliminary results from its Phase 2 trial, saying its vaccine induced neutralizing antibodies in “above 90%” of participants Read more CanSino Biologics Phase 2 CanSino Biologics, headquartered in Tianjin, is developing a coronavirus vaccine using the technology that led to a China-approved Ebola virus vaccine. CanSino’s approach involves taking a snippet of coronavirus’ genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. March 17: CanSino begins Phase 1 trial in China April 10: Based on preliminary data, CanSino says it will move into Phase 2 "soon" May 22: CanSino published data from a 108-subject trial, in which its vaccine generated a immune response in volunteers June 29: Chinese regulators provisionally approved CanSino's vaccine for military use July 20: CanSino publishes interim Phase 2 data showing a consistent antibody response but one that seemed to wane in older subjects Read more Inovio Pharmaceuticals Phase 1 Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, to produce the vaccine. April 6: Inovio doses first patient in Phase 1 trial June 30: Inovio says its vaccine led to an immune response in 94% of patients but does not provide data Read more Novavax Phase 1 Novavax is at work on a coronavirus vaccine that begins in the ovaries of an insect. The company’s vaccine platform involves genetically engineering a harmless virus and exposing it to cells isolated from worms. Those cells then churn out the proteins needed to stimulate antibodies, and those proteins become vaccines. For Covid-19, Novavax has isolated the spike protein found on the surface of the novel coronavirus. April 8: Novavax selects a vaccine candidate, planning to begin human trials in May with preliminary data in July May 26: Novavax begins Phase 1 trial, planning to enroll about 130 volunteers with data expected in July Aug. 4: Novavax presents detailed data from its Phase 1 trial, demonstrating an immune response with mostly mild side effects Read more Sanofi and GlaxoSmithKline Phase 1 Sanofi is employing the same technology it employs for flu vaccines, which uses a genetically modified version of a virus to create proteins that train the immune system to react. The company is combining its approach with GlaxoSmithKline's proprietary adjuvant, an additive that makes vaccines more potent. Feb. 18: Sanofi begins work on a coronavirus vaccine April 14: Sanofi partners with GlaxoSmithKline and plans to begin human trials in the second half of 2020 and generate pivotal data in 2021 Sept. 3. Sanofi and GlaxoSmithKline begin a 400-volunteer, Phase 1/2 trial, expect data in December Read More Johnson & Johnson Preclinical Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is using the same technology to develop a vaccine for the novel coronavirus. J&J’s vaccine is made by grafting the coronavirus genes that confer immunity onto a harmless virus, injecting it triggering an immune response without causing infection. March 30: J&J expects to begin Phase 1 by September, with a vaccine available for emergency use as soon as early 2021 Arcturus Therapeutics Preclinical Arcturus Therapeutics is pressing forward with a vaccine that relies on engineering RNA. The company plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle. The resulting vaccine, being developed in partnership with Duke University, promises a better immune response at a lower dose than competing mRNA approaches, according to the company. April 9: Arcturus plans to begin a Phase 1 trial in Singapore over the summer Clover Biopharmaceuticals and GlaxoSmithKline Preclinical Clover Biopharmaceuticals, headquartered in Chengdu, is developing a vaccine that would inject patients with a protein found on the surface of the novel coronavirus. GlaxoSmithKline is providing its proprietary adjuvant, an additive that makes vaccines more potent. Feb. 10: Clover identifies its vaccine candidate Feb. 24: GlaxoSmithKline provides its adjuvant CureVac Preclinical CureVac uses man-made mRNA to spur the production of proteins and protective antibodies. Like Moderna, the company got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. March 17: CureVac said it expects to have a candidate ready for animal testing by April, aiming to start a clinical study in the summer Imperial College London Preclinical Led by the immunologist Robin Shattock, Imperial College London is developing an RNA-based vaccine for the novel coronavirus. The scientists have engineered a virus-derived RNA strand that will get into cells, spur the production of the coronavirus’s signature protein, and then replicate itself. In animal studies, the vaccine has resulted in the generation of protective antibodies. April 17: With funding from the U.K. government, Imperial plans to complete preclinical work and begin human trials in June University of Queensland and GlaxoSmithKline Preclinical Australia’s University of Queensland, with funding from the Coalition for Epidemic Preparedness Innovations, has been developing a coronavirus vaccine since January. Queensland has a proprietary technology meant to make protein vaccines more effective at triggering an immune response. Called a molecular clamp, the university’s approach keeps the coronavirus’s key protein in its natural shape before grafting it onto the vaccine. April 9: Queensland plans to begin human trials in the third quarter Merck Preclinical Merck purchased a Vienna-based company called Themis, which is developing an experimental Covid-19 vaccine based on a measles vaccine. It also partnering with the nonprofit IAVI on the development of a coronavirus vaccine related to the company's existing Ebola vaccine. May 26: Merck says the Themis vaccine will enter human trials in a matter of weeks while the second candidate could reach the clinic by the end of the year Read more Sanofi and Translate Bio Preclinical Sanofi partnered with Translate Bio to develop potential vaccines using synthetic messenger RNA, which would compel the body to produce antibodies against the novel coronavirus. The two companies have worked together in the past on vaccines for infectuous disease. March 27: Sanofi and Translate Bio announce their collaboration but do not specify a development timeline

I'm in the Covid thread because it's more active than the OT one, and this topic caught my eye. The OP invited discussion and I am giving my thought (to those of the open minds on PPP who don't have me on ignore). That's wrong, but nice. You'll have to tell me what pandemic position I took is liberal. Don't worry. The powers that be think this place is good for TBD. Sorry you don't like differing opinions!

I am active in other politics discussions. Just not in this one for reasons stated and that’s my point.

I suggest that shutting it down improves TBD. You can do PPP in a million other places.

Maybe you missed the ignore list manifesto. And this board generally. Make the rest no politics like it usually is. Not that hard. You guys keep making it sound like it’s impossible to run a site with no politics but there are a million no-politics football boards out there. It isn’t rocket science. Again it’s all moot. SDS prefers to keep the positive energy that PPP contributes going so you’re all safe.

See how many people want to protect their echo chamber?

I was just pulling his leg on how much he posts. No worries. Happy to share a beer and a Bills game any time.

False. It doesn’t get archived as often. It’s not even close to TSW. 2 seconds of looking at who’s logged into each one will show you how off you are. Take away Rhino’s posts and the ppp content goes down by 40%! Take away every twitter paste by all of us and it goes down by 80%. If SDS wanted to chime in and shut it down, he’d have done so. So I think the site is safe.

Why “fake”? They do great aggregation work.

Probably been discussed here but Season Ticket Holders are getting NFL gamepass for free this year. Check your emails.